Hematology-Oncology – Page 5

Dose-Dense Stanford V Strategy Safely Spares Radiation in Most Pediatric Patients with Low-Risk Hodgkin Lymphoma

By MedXY 03/24/2026

The PHC HOD08 study demonstrates that an 8-week dose-dense modified Stanford V regimen achieves high complete response rates, allowing over 75% of low-risk pediatric Hodgkin lymphoma patients to avoid radiotherapy while maintaining an exceptional 5-year overall survival rate of 98.7%.

Hematology-Oncology news Oncology

Ph+ Status and Hyperleukocytosis: Redefining CNS Relapse Risk in Adult ALL Post-Transplant

By MedXY 03/19/2026

A large-scale retrospective study identifies Philadelphia chromosome positivity and high initial white blood cell counts as critical risk factors for central nervous system relapse in adult ALL patients following allogeneic HCT, suggesting a need for intensified prophylactic strategies.

Clinical Updates Hematology-Oncology news Pathology & Lab Medicine

Improving Survival in Advanced Proliferative CMML: The Prognostic Impact of Stringent Cytoreduction and Novel Flow Cytometric Biomarkers

By MedXY 03/19/2026

This review examines the impact of myeloproliferative control on survival in advanced CMML, highlighting the prognostic value of stringent cytoreduction and novel flow cytometric biomarkers such as classical monocytes and immature granulocytes.

Clinical Updates Hematology-Oncology news

Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results

By MedXY 03/19/2026

This review analyzes the Phase 3 Precision-T trial, demonstrating that Orca-T, a high-precision T-cell therapy, significantly improves chronic GVHD-free survival and reduces non-relapse mortality compared to standard-of-care prophylaxis in patients with hematologic malignancies.

Clinical Updates Hematology-Oncology Infectious Diseases news

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting

By MedXY 03/17/2026

This nationwide retrospective study in France highlights the rare but severe incidence of tuberculosis (TB) in Allo-HSCT recipients, identifying birth in high-prevalence countries as a primary risk factor and emphasizing the need for targeted latent TB screening.

Hematology-Oncology news

The NSUN2-FOSB Feedforward Loop: Unlocking m5C-Mediated Survival in Acute Myeloid Leukemia

By MedXY 03/16/2026

Researchers identify a novel NSUN2-FOSB-BCL2L1 regulatory axis in AML that drives leukemia stem cell self-renewal through m5C RNA methylation. This pathway offers a potential therapeutic target that spares normal hematopoiesis, suggesting a favorable therapeutic window for clinical translation.

Hematology-Oncology news

Beyond Blast Counts: How Menin Inhibition Redefines AML Immunophenotypes and Survival

By MedXY 03/16/2026

This study explores how the menin inhibitor revumenib induces significant immunophenotypic shifts in AML patients. Results show that over 50% of patients undergo lineage changes, and achieving MRD negativity remains the strongest predictor of long-term survival, necessitating new approaches to flow cytometry monitoring.

Clinical Updates Hematology-Oncology news Pathology & Lab Medicine

Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia

By MedXY 03/16/2026

This review explores oncofetal chondroitin sulfate (ofCS) as a revolutionary AML target. Unlike traditional antigens, ofCS is absent in normal bone marrow, allowing antibody-drug conjugates to eliminate leukemia cells with minimal hematotoxicity in preclinical models.

Clinical Updates Hematology-Oncology news

Standardizing Outcomes Research: A Robust Extraction Pipeline for Hematopoietic Stem Cell Transplantation Registry Data

By MedXY 03/13/2026

This review evaluates a novel open-source extraction pipeline designed to standardize and automate the processing of complex HSCT registry data, enhancing reproducibility and precision in clinical outcomes research.

Hematology-Oncology news

Precision Dosing in Chronic Myeloid Leukemia: Navigating the Intersection of TKI Efficacy and Long-term Tolerability

By MedXY 03/13/2026

This clinical review examines the management of treatment-emergent adverse events (TEAEs) in patients with chronic myeloid leukemia. It highlights strategies for dose optimization and proactive toxicity management to balance molecular response with long-term quality of life.

Hematology-Oncology news Oncology

Beyond Complexity: Why Molecular Features Still Dictate the Prognosis of Chronic Lymphocytic Leukemia

By MedXY 03/13/2026

Emerging data from UK clinical trials indicate that while high genomic complexity (HGC) correlates with poor outcomes in CLL, it often serves as a surrogate for other established high-risk markers like TP53 status and telomere length.

Hematology-Oncology news

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion

By MedXY 03/13/2026

A landmark study reveals that anti-BCMA bispecific antibodies, unlike anti-GPRC5D, deplete B-cell precursors from the small pre-B stage onward, explaining the significantly higher infection rates observed in multiple myeloma patients.

Cardiology Hematology-Oncology news

Abelacimab Shows Superior Safety Over Rivaroxaban for Older Adults with Atrial Fibrillation

By MedXY 03/12/2026

A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populations.

Hematology-Oncology news

Challenging the Incurability Paradigm: 15-Year Data Suggests a Cure for Advanced Follicular Lymphoma

By MedXY 03/09/2026

The 15-year follow-up of the SWOG S0016 trial demonstrates that approximately 42% of patients with advanced follicular lymphoma may be cured with initial CHOP-based chemoimmunotherapy, with relapse rates dropping significantly after 15 years.

Dermatology Hematology-Oncology news

Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case-Cohort Analysis of Clonal Inflammation

By MedXY 03/04/2026

MDS and CMML can present with lupuslike manifestations that represent a distinct entity of clonal inflammation rather than idiopathic autoimmunity. This study highlights the need for clone-directed therapies over standard lupus treatments.

Hematology-Oncology Infectious Diseases news

Molecular Mimicry Unveiled: How Somatic Hypermutation and Adenoviral Protein pVII Drive VITT

By MedXY 02/22/2026

Researchers have identified that a specific somatic hypermutation (K31E) in the IGLV3-21*02/03 allele triggers VITT by causing antibodies intended for adenoviral protein pVII to cross-react with Platelet Factor 4 (PF4), explaining the pathogenesis of this rare thrombotic condition.

Hematology-Oncology Nephrology news

Breaking the Cystine Barrier: Long-term Safety and Efficacy of CTNS-RD-04 Gene Therapy in Cystinosis

By MedXY 02/22/2026

A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.

Hematology-Oncology news Rheumatology

Europe’s Hidden Hyperinflammatory Crisis: HLH Mortality Rates Nearly Double Over a Decade

By MedXY 02/19/2026

A retrospective study across 29 European countries reveals that mortality from haemophagocytic lymphohistiocytosis (HLH) increased significantly between 2011 and 2021, with notable bimodal age peaks and geographical disparities suggesting widespread under-diagnosis.

$Cilta-cel Redefines Survival in Lenalidomide-Refractory Multiple Myeloma: Long-term Results from CARTITUDE-4$

Hematology-Oncology news

Cilta-cel Redefines Survival in Lenalidomide-Refractory Multiple Myeloma: Long-term Results from CARTITUDE-4

By MedXY 02/19/2026

The updated CARTITUDE-4 analysis demonstrates that cilta-cel significantly improves overall survival and progression-free survival compared to standard therapies in lenalidomide-refractory multiple myeloma patients after the first relapse, marking a potential shift in the treatment paradigm.

Hematology-Oncology news

Personalised T-Cell Activation Shows Promise in Overcoming Minimal Residual Disease in Chronic Lymphocytic Leukaemia

By MedXY 02/18/2026

A Phase 1 study demonstrates that iTAC-XS15-CLL01, a personalised multipeptide T-cell activator, induces robust immune responses in 95% of CLL patients on BTK inhibitors, offering a potential path to sustainable cancer control and eradication of minimal residual disease.